Terms: = Ovarian cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Treatment
129 results:
1. Methylation of brd4 by PRMT1 regulates brd4 phosphorylation and promotes ovarian cancer invasion.
Liu Y; Liu H; Ye M; Jiang M; Chen X; Song G; Ji H; Wang ZW; Zhu X
Cell Death Dis; 2023 Sep; 14(9):624. PubMed ID: 37737256
[TBL] [Abstract] [Full Text] [Related]
2. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
3. Arterial events in cancer patients treated with apixaban for venous thrombosis.
Larsen TL; Svalastoga M; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2023 Aug; 228():128-133. PubMed ID: 37327527
[TBL] [Abstract] [Full Text] [Related]
4. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells.
Quintela M; James DW; Pociute A; Powell L; Edwards K; Coombes Z; Garcia J; Garton N; Das N; Lutchman-Singh K; Margarit L; Beynon AL; Rioja I; Prinjha RK; Harker NR; Gonzalez D; Conlan RS; Francis LW
Clin Epigenetics; 2023 Apr; 15(1):63. PubMed ID: 37060086
[TBL] [Abstract] [Full Text] [Related]
5. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
[TBL] [Abstract] [Full Text] [Related]
6. Synergistic effect of PARP inhibitor and brd4 inhibitor in multiple models of ovarian cancer.
Huang Y; Liu C; You L; Li X; Chen G; Fan J
J Cell Mol Med; 2023 Mar; 27(5):634-649. PubMed ID: 36753396
[TBL] [Abstract] [Full Text] [Related]
7.
Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
[No Abstract] [Full Text] [Related]
8. Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1
Wang Q; Pan Y; Luo H; Zhang Y; Gao F; Wang J; Zheng J
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500678
[TBL] [Abstract] [Full Text] [Related]
9. Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric brd4 inhibitor/nitric oxide-donator.
Zhang Y; Pan Z; Chen C; Tan Y; Wang X; Wang L; Zhang L; Chen Y; He G
Eur J Med Chem; 2023 Jan; 246():114970. PubMed ID: 36470106
[TBL] [Abstract] [Full Text] [Related]
10. AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway.
Liu C; Huang Y; Qin T; You L; Lu F; Hu D; Xiao R; Qin X; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Zhang L; Cui Y; Sun C; Chen G
Cancer Lett; 2022 Mar; 528():31-44. PubMed ID: 34942306
[TBL] [Abstract] [Full Text] [Related]
11. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Colombo N; Moore K; Scambia G; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Kim JW; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
Gynecol Oncol; 2021 Oct; 163(1):41-49. PubMed ID: 34353615
[TBL] [Abstract] [Full Text] [Related]
12. Bromodomain-containing protein 4 inhibitor JQ1 promotes melanoma cell apoptosis by regulating mitochondrial dynamics.
Li L; Meng Y; Wu X; Li J; Sun Y
Cancer Sci; 2021 Oct; 112(10):4013-4025. PubMed ID: 34252226
[TBL] [Abstract] [Full Text] [Related]
13. p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.
Mak VC; Li X; Rao L; Zhou Y; Tsao SW; Cheung LW
Neoplasia; 2021 Jul; 23(7):718-730. PubMed ID: 34144267
[TBL] [Abstract] [Full Text] [Related]
14. Clinical perspectives of BET inhibition in ovarian cancer.
Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Cell Oncol (Dordr); 2021 Apr; 44(2):237-249. PubMed ID: 33469840
[TBL] [Abstract] [Full Text] [Related]
15. The Application of a Low-temperature Physical Plasma Device Operating Under Atmospheric Pressure Leads to the Production of Toxic NO
Kletschkus K; Haralambiev L; Nitsch A; Pfister F; Klinkmann G; Kramer A; Bekeschus S; Mustea A; Stope MB
Anticancer Res; 2020 May; 40(5):2591-2599. PubMed ID: 32366404
[TBL] [Abstract] [Full Text] [Related]
16. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract] [Full Text] [Related]
17. miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: A systematic literature review.
Guo CM; Liu SQ; Sun MZ
Neoplasma; 2020 Mar; 67(2):215-228. PubMed ID: 31884798
[TBL] [Abstract] [Full Text] [Related]
18. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract] [Full Text] [Related]
19. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein brd4.
Villar-Prados A; Wu SY; Court KA; Ma S; LaFargue C; Chowdhury MA; Engelhardt MI; Ivan C; Ram PT; Wang Y; Baggerly K; Rodriguez-Aguayo C; Lopez-Berestein G; Ming-Yang S; Maloney DJ; Yoshioka M; Strovel JW; Roszik J; Sood AK
Mol Cancer Ther; 2019 Feb; 18(2):421-436. PubMed ID: 30420565
[TBL] [Abstract] [Full Text] [Related]
20. brd4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Sun C; Yin J; Fang Y; Chen J; Jeong KJ; Chen X; Vellano CP; Ju Z; Zhao W; Zhang D; Lu Y; Meric-Bernstam F; Yap TA; Hattersley M; O'Connor MJ; Chen H; Fawell S; Lin SY; Peng G; Mills GB
Cancer Cell; 2018 Mar; 33(3):401-416.e8. PubMed ID: 29533782
[TBL] [Abstract] [Full Text] [Related]
[Next]
